Fig. 3
From: PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis
PRMT5 regulates aerobic glycolysis in vitro and in vivo a. The glucose uptake assay results suggested that PRMT5 knockdown decreased the glucose intake capacity of MIA PaCa-2 and SW1990 cells. b. The lactate level assay results indicated a decrease in lactate levels when PRMT5 was silenced in MIA PaCa-2 and SW1990 cells. c-d. A Seahorse extracellular flux analyzer was used to measure the ECAR, and the results indicated that decreased PRMT5 expression resulted in increased glycolysis in and glycolytic capacity of pancreatic cancer cells. e. Representative PRMT5 staining and 18F-FDG-PET/CT images for the indicated patients. f. Patients with high PRMT5 expression exhibited high levels of SUVmax values obtained by 18F-FDG-PET/CT imaging. g. Representative micro-PET/CT image of the subcutaneous xenograft mouse model. h. PRMT5 knockdown decreased 18F-FDG uptake by subcutaneous tumors, as reflected by the SUVmax value, reinforcing the roles of PRMT5 in promoting glycolysis in vivo